{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:15:44Z","timestamp":1790082944771,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.jconrel.2011.11.022","type":"journal-article","created":{"date-parts":[[2011,12,3]],"date-time":"2011-12-03T18:43:14Z","timestamp":1322937794000},"page":"225-231","source":"Crossref","is-referenced-by-count":65,"title":["Ocular antisense oligonucleotide delivery by cationic nanoemulsion for improved treatment of ocular neovascularization: An in-vivo study in rats and mice"],"prefix":"10.1016","volume":"160","author":[{"given":"Tal","family":"Hagigit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Abdulrazik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faty","family":"Valamanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Behar-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Benita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2011.11.022_bb0005","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s11095-004-7674-6","article-title":"Topical delivery of anti-sense oligonucleotides using low-frequency sonophoresis","volume":"21","author":"Tezel","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/17425240902992894","article-title":"Controlled delivery of antisense oligonucleotides: a brief review of current strategies","volume":"7","author":"Zhao","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0015","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0022-3565(25)39459-0","article-title":"Disposition of the 14C-labled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats","volume":"267","author":"Cossum","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0020","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1073\/pnas.88.17.7595","article-title":"Pharmacokinetics, biodistribution and stability of oligonucleotide phosphorothioates in mice","volume":"88","author":"Agrawal","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0025","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0026-895X(25)10208-3","article-title":"Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioated","volume":"45","author":"Sands","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/ard.1991.1.141","article-title":"Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3\u2032 exonuclease in plasma","volume":"1","author":"Eder","year":"1991","journal-title":"Antisense Res. Dev."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/ICU.0b013e32834597d9","article-title":"Preferred therapies for neovascular age-related macular degeneration","volume":"3","author":"Chiang","year":"2011","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0040","first-page":"1350","article-title":"Rosenfeld PJ","volume":"9","author":"Zarbin","year":"2010","journal-title":"Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina"},{"key":"10.1016\/j.jconrel.2011.11.022_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/OPTH.S2094","article-title":"Age-related macular degeneration: current treatments","volume":"3","author":"Hubschman","year":"2009","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1023\/A:1018806425667","article-title":"Submicron cationic emulsions as a new delivery system for oligonucleotides","volume":"16","author":"Teixeira","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0055","first-page":"1334","article-title":"Ocular gene therapy: a review of nonviral strategies","volume":"12","author":"Andrieu-Soler","year":"2006","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0168-3659(00)00327-8","article-title":"Factors influencing the oligonucleotides release from O\/W submicron cationic emulsions","volume":"70","author":"Teixeira","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2011.11.022_bb0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejpb.2008.03.005","article-title":"The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions","volume":"70","author":"Hagigit","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jconrel.2010.04.013","article-title":"Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye","volume":"145","author":"Hagigit","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2011.11.022_bb0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejpb.2004.03.033","article-title":"The potential of lipid emulsion for ocular delivery of lipophilic drugs","volume":"58","author":"Tamilvanan","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00417-007-0542-4","article-title":"Inhibition of corneal angiogenesis by ascorbic acid in the rat model","volume":"245","author":"Peyman","year":"2007","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0090","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","article-title":"Animal models of choroidal and retinal neovascularization","volume":"29","author":"Grossniklaus","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.chemphyslip.2004.04.003","article-title":"Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions","volume":"131","author":"Rabinovich-Guilatt","year":"2004","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.jconrel.2011.11.022_bb0105","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0168-3659(98)00107-2","article-title":"Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn","volume":"57","author":"Klang","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2011.11.022_bb0115","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1081\/PDT-100102035","article-title":"Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution","volume":"5","author":"Klang","year":"2000","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0120","first-page":"315","article-title":"Ocular delivery of cyclosporin A I. Design and characterization of cyclosporin A-loaded positively-charged submicron emulsion","volume":"11","author":"Tamilvanan","year":"2001","journal-title":"S.T.P. Pharma Sci."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0125","first-page":"321","article-title":"Ocular delivery of cyclosporin A II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclopsorin A","volume":"11","author":"Abdulrazik","year":"2001","journal-title":"S.T.P. Pharma Sci."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v25.i6.10","article-title":"Nanoparticle\u2013cell interactions: drug delivery implication","volume":"25","author":"Harush-Frenkel","year":"2008","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00441-009-0908-5","article-title":"Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model","volume":"339","author":"Gong","year":"2010","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/02713680802607740","article-title":"The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas","volume":"34","author":"Oh","year":"2009","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2011.11.022_bb0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0165-5728(98)00075-7","article-title":"Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization","volume":"89","author":"Vinores","year":"1998","journal-title":"J. Neuroimmunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911010753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911010753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T20:26:04Z","timestamp":1741983964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365911010753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0168365911010753"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2011.11.022","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}